276 related articles for article (PubMed ID: 24798350)
1. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
Bao J; Yue T; Li T; He DY; Bao YX
Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
[TBL] [Abstract][Full Text] [Related]
2. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
4. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
7. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
Bresnihan B; Alvaro-Gracia JM; Cobby M; Doherty M; Domljan Z; Emery P; Nuki G; Pavelka K; Rau R; Rozman B; Watt I; Williams B; Aitchison R; McCabe D; Musikic P
Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
[TBL] [Abstract][Full Text] [Related]
13. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
[TBL] [Abstract][Full Text] [Related]
14. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
16. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
[TBL] [Abstract][Full Text] [Related]
17. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
[TBL] [Abstract][Full Text] [Related]
20. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]